Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT02868476 |
| Other study ID # |
201606056RINA |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
August 19, 2016 |
| Est. completion date |
July 30, 2024 |
Study information
| Verified date |
August 2022 |
| Source |
National Taiwan University Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Clinical and subclinical thyroid disease is usually used to describe patients with mild
symptoms correlated to hyperthyroid or hypothyroid state. Therapeutic decision for clinical
and subclinical thyroid dysfunction should be considered individually. But long term outcome
for treatment of such functional and structural thyroid diseases had not been recorded
delicately in Taiwan. Further investigations should be observed in the future.The purpose of
this study is aiming for early prevention and detection the potential risk factors for
thyroid diseases in Taiwan.
Description:
Clinical and subclinical thyroid disease is usually used to describe patients with mild
symptoms correlated to hyperthyroid or hypothyroid state. Thyroid ultrasonography could
differentiate benign or malignant nodular lesion, together with fine needle aspiration
cytology and surgical pathology. Thyrotropin (TSH, thyroid stimulating hormone) is the
pivotal investigation in laboratory diagnosis to define subclinical thyroid diseases. An
elevated TSH with normal free thyroxine and triiodothyronine levels in serum is defined to be
subclinical hypothyroidism, and a subnormal TSH with normal thyroid hormone concentrations to
be subclinical hyperthyroidism. Generally, the prevalence of subclinical hypothyroidism and
hyperthyroidism were reported as 4% -10% & 1%-2% in general population, respectively.
Although subclinical thyroid disease is prevalent, there is still no consensus for screening
clinical and subclinical thyroid disease, including hyperthyroidism, hypothyroidism, nodular
goiter and thyroid cancer. Under consideration of age, gender or familial history of
autoimmune thyroid disease. However, screening for thyroid dysfunction should be considered
in some high risk patients, including 1) elderly; 2) history of atrial fibrillation; 3)
previous thyroid disease history; 4) other confirmed autoimmune diseases; 5) neck exposure of
radiation (for example, nasopharyngeal cancer, post-radiation); 6) family history of probable
autoimmune thyroid disease, and 7) pregnant state with prior thyroid disease history.
Therapeutic decision for clinical and subclinical thyroid dysfunction should be considered
individually. Therapeutic options will be anti-thyroid medications and/or radioactive iodine,
and thyroidectomy could be considered with larger goiters for hyperthyroidism. For clinical
and subclinical hypothyroidism, the therapeutic consideration should be aimed on reduction of
progression to overt hypothyroidism, improving heart function, correction of dyslipidemia,
and relieving senescence depressive mood. Thyroid ultrasonography will help us to keep long
term observation of thyroid structural change. But long term outcome for treatment of such
functional and structural thyroid diseases had not been recorded delicately in Taiwan.
Further investigations should be observed in the future. We hope to check the relationship
between various thyroid diseases and biochemical survey/ultrasonography. The purpose of this
study is aiming for early prevention and detection the potential risk factors for thyroid
diseases in Taiwan.
